Yahoo Web Search

Search results

1. Ovid Therapeutics - Local Result

   • 

   • A
     Ovid Therapeutics Inc

     Pharmaceutical Manufacturer

     441 9th Ave, #14, New York, NY · (646) 661-7661
     
     Website
   Add or update your business

2. ovidrx.comHome - Ovid Therapeutics

   ovidrx.com

   • Cached

   We strive to conquer epilepsies and brain conditions with courageous science. We are developing a next generation of targeted small molecule therapies that seek to reduce seizures and deliver improved safety and tolerability.

   • News

     News - Home - Ovid Therapeutics

   • Events & Presentations

     Events & Presentations - Home - Ovid Therapeutics

   • Stock Information

     Stock Information - Home - Ovid Therapeutics

     Board of Directors

     · Scientific Presentations

   • Governance

     Governance - Home - Ovid Therapeutics

   • Resources

     Corporate Profile. Ovid Therapeutics is a New York-based...

   • Our Story

     Ovid Therapeutics is a biopharmaceutical company striving to...

   • Our Pipeline

     We are cultivating a differentiated pipeline of small...

   • Leadership

     our leadership & governance Our management team collectively...

   • Contact Us

     Our Corporate Headquarters Hudson Commons 441 9th Avenue New...

   • OV888

     overview. Ovid entered a collaboration with Graviton...

3. finance.yahoo.com › quote › OVIDOvid Therapeutics Inc. (OVID) Stock Price, News, Quote ...

   finance.yahoo.com › quote › OVID

   • Cached

   Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in...

4. finance.yahoo.com › news › ovid-therapeutics-reportsOvid Therapeutics Reports Business Updates and First Quarter ...

   finance.yahoo.com › news › ovid-therapeutics-reports

   • Cached

   May 14, 2024 · Tue, May 14, 2024, 8:00 AM 11 min read. In this article: OVID. Ovid Therapeutics Inc. Takeda has completed two Phase 3 trials studying soticlestat as a treatment for Lennox-Gastaut syndrome...

5. Top Stories

   • 

     Investorplace News on MSN.com

     OVID Stock Earnings: Ovid Therapeutics Beats EPS, Beats Revenue for Q1 2024

     2 weeks ago

   • Business Insider

     Buy Rating for Ovid Therapeutics Based on Novel SE Drug Candidates OV329 and OV350

     In a report released yesterday, Thomas Shrader from BTIG maintained a Buy rating on Ovid Therapeutics (OVID – Research Report), with a

     1 week ago

   • Business Insider

     Ovid Therapeutics Reports Business Updates and First Quarter 2024 Financial Results

     Takeda has completed two Phase 3 trials studying soticlestat as a treatment for Lennox-Gastaut syndrome and Dravet syndrome; topline data are

     2 weeks ago

   • Zacks.com on MSN.com

     Ovid Therapeutics (OVID) Reports Q1 Loss, Tops Revenue Estimates

     Ovid Therapeutics (OVID) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.19 per share a year ago. These figures are adjusted for non-recurring items.

     2 weeks ago

   View all

6. www.nasdaq.com › press-release › ovid-therapeuticsOvid Therapeutics Reports Business Updates, Fourth Quarter ...

   www.nasdaq.com › press-release › ovid-therapeutics

   • Cached

   Dec 31, 2023 · NEW YORK, March 08, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to meaningfully improving the lives of people affected by rare...